The downward pressure and sharp price drops experienced by Codexis stock are primarily driven by investor concerns regarding the company's underlying financial health, ongoing operational unprofitability, and negative revenue growth trends over recent reporting periods. As a clinical-stage biotechnology enterprise, Codexis has faced negative operating margins and compressed revenue metrics from its pharmaceutical biocatalysis and ECO Synthesis manufacturing platform segments. Market participants often react negatively to persistent net losses, lack of near-term profitability catalysts, and high cash burn rates typical of small-cap biotech firms, leading to cautious institutional selling and reduced valuation multiples across public equity markets.